trial

A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.

NCTId NCT06356389
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 60 (actual)
Sponsored by Zhejiang Jingxin Pharmaceutical Co., Ltd.
Primary completion 2022-12-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2022-03-02
Primary completion
2022-12-27
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
JX11502MA

Sponsors

Zhejiang Jingxin Pharmaceutical Co., Ltd.Lead Sponsor
Shanghai Mental Health CenterCollaborator

Sites

1 total
Shanghai, China

Linked catalysts

1
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA — primary completion2022-12-27

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE1,PHASE2
Primary Completion Date
2022-12-27
Status
COMPLETED
relationships
The graph out of here
drug
JX11502MA
drug
lead_sponsor
Zhejiang Jingxin Pharmaceutical Co., Ltd.
company
collaborator
Shanghai Mental Health Center
company
indication
Schizophrenia
indication
Schizophrenia
indication